Application of mRNA vaccines in head and neck cancer immunotherapy: Current progress and challenges

Critical Reviews in Oncology/Hematology · Published 2026-07-28 · DOI 10.1016/j.critrevonc.2026.105501

Authors (9)

Linrong Wu, Hongshuai Liu, Zhikai Wang, Jiangyu Yan, Ke Xu, Dong Ye, Zhounan Zhu, Yizhen Xiang, Junjun Zhang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wu, L., Liu, H., Wang, Z., et al. (2026). Application of mRNA vaccines in head and neck cancer immunotherapy: Current progress and challenges. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2026.105501

Related articles

• mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics · Cancer Innovation · 2025 · Cites or is cited by this article
• Cancer vaccines: advances, hurdles, and future directions · Exploration of Targeted Anti-tumor Therapy · 2025 · Cites or is cited by this article
• A real-world study of the effectiveness and safety of low-dose immunotherapy in addition to oral metronomic chemotherapy in recurrent and metastatic head and neck squamous cell carcinoma · Journal of the Egyptian National Cancer Institute · 2026 · Cites or is cited by this article
• TROP-2 in solid tumors: From oncogenic driver to therapeutic target with antibody-drug conjugates · Critical Reviews in Oncology/Hematology · 2026 · Same journal
• Circulating tumour DNA and molecular residual disease in oesophageal cancer: Clinical readiness, evidence gaps and trial-ready applications · Critical Reviews in Oncology/Hematology · 2026 · Same journal
• Molecular mechanisms of targeted therapy in breast cancer: An integrated signaling network perspective · Critical Reviews in Oncology/Hematology · 2026 · Same journal
• The adipose microenvironment in colorectal cancer: Navigating the nexus of inflammation, metabolism, and metastatic reprogramming · Critical Reviews in Oncology/Hematology · 2026 · Same journal
• Biomimetic nanoparticles for metastatic breast cancer: Advancing targeted drug delivery beyond conventional nanomedicine · Critical Reviews in Oncology/Hematology · 2026 · Same journal
• Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy · Critical Reviews in Oncology/Hematology · 2026 · Same journal
• Extracellular vesicle-mediated immunity-coagulation interaction in cancer-associated thrombosis during the immunotherapy era · Critical Reviews in Oncology/Hematology · 2026 · Same journal